Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.83 |
| ▸ | NPC1 | O15118 | 10/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | TP53 | P04637 | 3/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799157 | 0.91 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL674669 | 0.88 | NPC1 (0.86) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL3669771 | 0.86 | PGR (0.67) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL30341896 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL22192206 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL6361263 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8770881 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8769709 | 0.86 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL21798720 | 0.86 | KMT2A (0.76) | RAB9ANPC1TP53KDM4EMAPT | |
| SCHEMBL3679372 | 0.86 | KMT2A (0.76) | RAB9ANPC1TP53KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20120094038-A1 | USE OF HUMIDITY STABLE YELLOW FLUORESCENT PIGMENTS IN SECURITY APPLICATIONS | HONEYWELL INTERNATIONAL INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-20060106074-A1 | ER-B-SELECTIVE LIGANDS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| EP-1478631-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003045930-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | RAB9A 1349/4885NPC1 2588/4885SMN1; SMN2 1899/4885 |
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | RAB9A 163/4885NPC1 128/4885SMN1; SMN2 410/4885 |
| US-20060106074-A1 | ER-B-SELECTIVE LIGANDS | ESR2, ESRRB, ESRRA | RAB9A 877/4885NPC1 1711/4885SMN1; SMN2 3043/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | RAB9A 1262/4885NPC1 2976/4885SMN1; SMN2 1878/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | RAB9A 160/4885NPC1 137/4885SMN1; SMN2 475/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | RAB9A 1897/4885NPC1 3474/4885SMN1; SMN2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.